Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144963 | 1.00 | THRB (0.38) | THRBATMKDM4EGAAMAP3K7 | |
| SCHEMBL3930316 | 0.83 | MYC (0.40) | THRBATMKDM4EGAAMAP3K7 | |
| SCHEMBL3930323 | 0.83 | MYC (0.40) | THRBATMKDM4EGAAMAP3K7 | |
| SCHEMBL10313863 | 0.82 | DPP4 (0.47) | KDM4EALDH1A1CNKSR1CA12CA1 | |
| SCHEMBL29446160 | 0.82 | DPP4 (0.47) | KDM4EALDH1A1CNKSR1CA12CA1 | |
| SCHEMBL10314039 | 0.82 | DPP4 (0.47) | KDM4EALDH1A1CNKSR1CA12CA1 | |
| SCHEMBL12094142 | 0.78 | CYP1A2 (0.34) | ALDH1A1MAP4K4HSD17B10PLAUMEN1 | |
| SCHEMBL10323668 | 0.77 | CYP1A2 (0.36) | KDM4EALDH1A1MAP4K4HSD17B10PLAU | |
| SCHEMBL25345948 | 0.76 | PLAU (0.44) | KDM4EGAAMAP3K7TAB1ALDH1A1 | |
| SCHEMBL4715171 | 0.76 | MEN1 (0.42) | THRBKDM4EGAAMAP3K7TAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283642-B1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RES CENTER HOLDING B V (NL) | 2023-10-11 | — | — | EP | disclosed |
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2022-02-24 | — | — | US | disclosed |
| US-11208696-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2021-12-28 | — | — | US | disclosed |
| US-20190211401-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-07-11 | — | — | US | disclosed |
| EP-3129374-B1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2018-12-19 | — | — | EP | disclosed |
| US-9856258-B2 | (5,6-dihydro)pyrimido[4,5-E]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2018-01-02 | — | — | US | disclosed |
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-04-06 | — | — | US | disclosed |
| EP-3129374-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | Netherlands Translational Research Center B.V. (NL) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015155042-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2015-10-15 | — | — | WO | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | DHFR, CYP2D6, DPYD | THRB 1117/4885ATM 2285/4885KDM4E 754/4885 |
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | TTBK1, CTNNB1, TTK | THRB 120/4885ATM 304/4885KDM4E 2628/4885 |
| US-20190211401-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | TTBK1, CTNNB1, TTK | THRB 120/4885ATM 304/4885KDM4E 2628/4885 |
| US-11208696-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | TTBK1, CTNNB1, TTK | THRB 120/4885ATM 304/4885KDM4E 2628/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | THRB 3857/4885ATM 4825/4885KDM4E 1732/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | THRB 3873/4885ATM 4830/4885KDM4E 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.